Table 2.
Description of Inhalation Therapies Used in the Study Population (N=4796)
| Therapies, Only Used, n (%) | COPD Patients |
|---|---|
| Monotherapy | |
| SABA | 23 (0.5) |
| SAMA | 20 (0.4) |
| LABA | 1 (0.02) |
| LAMA | 1875 (39.1) |
| ICS | 9 (0.2) |
| Dual therapy | |
| LABA/ICS | 689 (14.4) |
| LAMA+ICS | 7 (0.1) |
| LAMA/LABA | 5 (0.1) |
| Triple therapy | |
| LAMA+LABA/ICS | 1872 (39.0) |
| Other therapies | |
| LABA/ICS+ICS | 1 (0.02) |
| LABA/ICS+LAMA/LABA | 1 (0.02) |
| SABA+SAMA | 1 (0.02) |
| SABA+ICS | 1 (0.02) |
| SABA or SAMA+LABA/ICS | 47 (1.0) |
| SABA or SAMA+LAMA | 83 (1.7) |
| SAMA+LABA/LAMA | 3 (0.06) |
| SABA or SAMA+LAMA+LABA/ICS | 123 (2.6) |
| SABA+SAMA+ LABA/ICS | 1 (0.02) |
| SABA+SAMA+LAMA+LABA/ICS | 3 (0.06) |
| SAMA +LAMA+LABA/ICS+ICS | 1 (0.02) |
Notes: LABA/ICS means LABA and ICS are in an inhaler. LAMA/LABA also means they are in an inhaler. “+” means “and”, it was defined to show the all inhalations with different inhalers used simultaneously by patients.
Abbreviations: SABA, short-acting β2-agonist; SAMA, short-acting muscarinic agonist; LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist; ICS, inhaled corticosteroids; NIPPV, non-invasive positive pressure ventilation.